e-learning
resources
Madrid 2019
Sunday, 29.09.2019
Treatment of asthma with monoclonal antibodies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma
S. Korn (Mainz, Germany), L. Ehrhard (Mainz, Germany), S. Voigt (Mainz, Germany), R. Buhl (Mainz, Germany)
Source:
International Congress 2019 – Treatment of asthma with monoclonal antibodies
Session:
Treatment of asthma with monoclonal antibodies
Session type:
Poster Discussion
Number:
1653
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Korn (Mainz, Germany), L. Ehrhard (Mainz, Germany), S. Voigt (Mainz, Germany), R. Buhl (Mainz, Germany). Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma. 1653
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Real-life impact of weight in severe eosinophilic asthma patients treated with benralizumab
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021
Real-life treatment of severe eosinophilic asthma with mepolizumab
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Mepolizumab in real-life treatment of severe eosinophilic asthma
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Super-responder analysis and real-world one year effectiveness of benralizumab in severe eosinophilic asthma
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
Real-world effectiveness of reslizumab for severe eosinophilic asthma (SEA)
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Which patients should be treated with anti-IgE?
Source: Eur Respir Rev 2007; 16: 85-87
Year: 2007
Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy
Source: Eur Respir Rev 2007; 16: 73-77
Year: 2007
Stopping
versus
continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)
Source: Eur Respir J, 59 (1) 2100396; 10.1183/13993003.00396-2021
Year: 2022
Clinical response to mepolizumab in patients with severe eosinophilic asthma
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
Source: ERJ Open Res, 7 (4) 00465-2021; 10.1183/23120541.00465-2021
Year: 2021
Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Evaluating the efficacy of omalizumab in severe persistent asthma patients
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond
Source: Eur Respir J 2006; 28: Suppl. 50, 440s
Year: 2006
Real-world treatment patterns of benralizumab therapy for patients with severe asthma
Source: Virtual Congress 2020 – Diagnosis and management of asthma
Year: 2020
Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept